Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Active (Oseltamivir)-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients 1 to <12 Years of Age With Influenza-Like Symptoms

Next Previous
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Active (Oseltamivir)-Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Otherwise Healthy Pediatric Patients 1 to <12 Years of Age With Influenza-Like Symptoms

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baloxavir-marboxil (Primary) ; Oseltamivir
  • Indications Influenza virus infections
  • Focus Adverse reactions; Registrational
  • Acronyms MINISTONE-2
  • Sponsors Genentech; Roche

    • Most Recent Events

    • 17 Aug 2023 Results of post hoc analysis evaluating the safety and efficacy of baloxavir versus oseltamivir in children aged 5-11 years with influenza, published in the Pediatric Infectious Disease Journal
    • 04 Jul 2023 According to a Shionogi media release, the company has filed for a supplemental new drug application (sNDA) of Xofluza (baloxavir marboxil) in Taiwan for treatment and post-exposure prophylaxis for influenza virus infection for pediatrics aged 5 to under 12 years.
    • 11 Aug 2022 According to a Genentech media release, Dr. Pedro Piedra is the investigator of the study

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top